Intravesical prostatic protrusion predicts clinical progression of benign prostatic enlargement in patients receiving medical treatment

International Journal of Urology - Tập 17 Số 1 - Trang 69-74 - 2010
Lui Shiong Lee1, Hong Gee Sim2, Kok Bin Lim2, Delin Wang3, Keong Tatt Foo2
1Department of Urology, Singapore General Hospital, Singapore
2Department of Urology, Singapore General Hospital, Singapore, and
3Department of Urology, The First Affiliated Hospital, Chongqing University of Medical Sciences, Chongqing, China

Tóm tắt

Objectives:  To assess intravesical prostatic protrusion (IPP) as a novel predictor of clinical progression in patients with benign prostatic enlargement (BPE).Methods:  All patients attending the outpatient clinic at our institution who were being treated for lower urinary tract symptoms (LUTS) secondary to BPE between January 1997 and December 2003 were recruited into the study. International Prostate Symptom Score (IPSS) scores, uroflowmetry parameters, post‐void residual urine volume (PVR), IPP and serum prostate‐specific antigen (PSA) were collected. IPP was classified into Grade 1, 2 or 3. Patients were stratified to different treatment options including watchful waiting, alpha blockers or 5‐alpha reductase inhibitors. Those who developed high post‐void residual urine volume (>100 mL), acute urinary retention or a deterioration of at least 4 points in IPSS score were considered to have disease progression. Using the Grade 1 IPP group as a reference, the odds ratio for clinical progression of Grade 2 and Grade 3 IPP were calculated by using multivariate analysis.Results:  A total of 259 patients with a mean age of 63 years (range 50–90 years) and mean follow‐up time of 32 months were available for analysis. Fifty‐two patients were found to have clinical progression. Odds ratio for progression of a Grade 2 IPP was 5.1 (95% confidence interval [CI] 1.6–16.2) and that of a Grade 3 IPP was 10.4 (95% CI 3.3–33.4).Conclusion:  A higher IPP grade is associated with a higher risk of clinical progression in BPE. IPP is a useful non‐invasive predictor for clinical progression in BPE.

Từ khóa


Tài liệu tham khảo

10.1016/S0022-5347(17)35405-8

Li MK, 2007, An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function, BJU Int, 101, 197

10.1016/S0022-5347(01)64508-7

10.1016/S0090-4295(98)00654-2

10.1016/S0302-2838(02)00021-0

10.1046/j.1464-410X.2003.04088.x

10.1016/j.urology.2004.10.014

10.1097/01.ju.0000095474.86981.00

10.1016/j.juro.2007.03.116

10.1046/j.1442-2042.2002.00453.x

Foo KT, Chia SJ, David C, 2005, Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia

Randalls A, 1931, Surgical Pathology of Prostatic Obstruction

10.1111/j.1442-2042.2006.01611.x

10.1016/S0090-4295(98)00020-X

10.1080/00365590310014760

10.1016/S0022-5347(01)66780-6

10.1111/j.1464-410X.1995.tb07421.x

10.1056/NEJMoa030656

Thông tin
Thông tin xuất bản

International Journal of Urology

Tập 17 Số 1

69-74

Thông tin tác giả